BioSpace News Archive

Milestone Pharmaceuticals Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a clinical and corporate update.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will present at two upcoming investor conferences.

Verrica Pharmaceuticals Inc. today announced financial results for the third quarter ended September 30, 2021.

Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021 .

Elevation Oncology, Inc. today announced financial results for the quarter ended September 30, 2021.

Arrowhead Pharmaceuticals Inc. announced additional interim clinical data from AROHSD1001, an ongoing Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference therapeutic being developed as a treatment for patients with alcohol-related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis.

Talaris Therapeutics, Inc. (Nasdaq: TALS), today reported financial results for the three- and nine-month periods ended September 30, 2021, and provided an update on its business.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, presented a poster with preclinical data on its TriTAC-XR T cell engager platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer in Washington, D.C.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association Scientific Sessions, to be held virtually Nov. 13-15, 2021.

OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, announced the presentation of new preclinical data at the Society for Immunotherapy of Cancer’s 36th Annual Meeting & Pre-Conference Programs being held November 10-14, 2021, both virtually and in Washington, D.C.